SecBot SecBot
PRESS-RELEASE ·Filed Apr 24, 2026

ANAB

AnaptysBio, Inc.
BULLISH
Impact 7/10
Horizonmonths Processed6mo ago WireGlobeNewswire
Press release · Contract
Actionable Insight ▲ Bullish

The ruling removes near-term downside risk to royalty rates and strengthens AnaptysBio’s negotiating and litigation position ahead of the July 2026 trial. Traders should monitor Jemperli sales trends and trial developments as catalysts for valuation re-rating, especially if reversion rights gain legal traction.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$58.88
T+0 close · Apr 24, 2026 · via day close
Latest settled
−8.70%
T+60 · $53.76
Vs SPY
−13.78%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 24 $58.88entry
  2. T+1 · 7mo ago +13.09%α +12.93% · $66.59
  3. T+5 · 7mo ago +11.63%α +10.72% · $65.73
  4. T+20 · 6mo ago +2.60%α −1.43% · $60.41
  5. T+60 · 4mo ago −8.70%α −13.78% · $53.76
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

AnaptysBio announced a favorable court ruling in its ongoing litigation with Tesaro/GSK, with the Delaware Chancery Court dismissing Tesaro’s claim of anticipatory breach and upholding the current royalty structure for Jemperli. The decision preserves AnaptysBio’s right to receive tiered royalties (up to 25%) and sets the stage for a July 2026 trial on Anaptys’ claims of material breach and reversion rights.

Key Facts

  • Delaware Chancery Court dismissed Tesaro’s anticipatory breach claim against AnaptysBio.
  • Court rejected Tesaro’s request to reduce royalty rates on Jemperli sales.
  • Current royalty structure upheld: 8% below $1B, 12% between $1B–$1.5B, 20% between $1.5B–$2.5B, and 25% above $2.5B in annual net sales.
  • Trial on AnaptysBio’s claims, including right to reversion of Jemperli, scheduled for July 14–17, 2026.
  • Anaptys claims Tesaro breached exclusivity, diligence, and notice obligations under the Collaboration Agreement.

Financial Impact

Preserves potential royalty stream worth hundreds of millions of dollars; Jemperli sales were $1.2B in 2025 (implied from royalty tiers and public data). At current trajectory, Anaptys could receive ~$144M annually (12% of $1.2B), with upside to 20–25% as sales grow.

royalty revenuecash flowvaluation

Risk Factors

  • Final outcome of trial in July 2026 remains uncertain; reversion of Jemperli is not guaranteed.
  • GSK/Tesaro may appeal or pursue further legal action.
  • Royalty revenue dependent on continued commercial performance of Jemperli.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3281057

Track record

28 reports on ANAB

Performance horizon

9 of 18 bullish or bearish reports moved the stock their way by T+1. Best: +41.26% at T+60 after the Mar 3, 2026 report. 12 of 18 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $46.25 Now $45.73 −1.12% settles Nov 17
  2. Nov 12, 20264d ago Press Release Bearish 4/10 Entry $46.25 to $45.73 Now $45.73 +1.12% ▲ +1.12% −0.79% vs SPY
  3. Nov 6, 202610d ago Institutional Cluster Neutral 2/10 Entry $46.45 to $47.97 Now $45.73 −1.55% ▲ +3.27% +0.91% vs SPY
  4. Sep 21, 20268w ago Press Release Neutral 5/10 Entry $53.92 to $50.77 Now $45.73 −15.19% ▼ −5.84% −5.12% vs SPY
  5. Aug 12, 202613w ago Institutional Cluster Bullish 5/10 Entry $56.02 to $58.47 Now $45.73 −18.37% ▲ +4.37% +4.57% vs SPY
  6. Jun 29, 202620w ago 144 Bearish 6/10 Entry $67.50 to $65.43 Now $45.73 +32.25% ▲ +3.07% +2.93% vs SPY
  7. Jun 29, 202620w ago DEFA14A Neutral 2/10 Entry $67.50 to $65.43 Now $45.73 −32.25% ▼ −3.07% −2.93% vs SPY
  8. Jun 26, 202620w ago 144 Bearish 6/10 Entry $65.97 to $67.50 Now $45.73 +30.68% ▼ −2.32% −1.54% vs SPY
  9. Jun 22, 202621w ago 8-K Neutral 2/10 Entry $59.43 to $58.48 Now $45.73 −23.05% ▼ −1.60% −1.55% vs SPY
  10. Jun 17, 202621w ago 144 Bearish 5/10 Entry $57.51 to $59.99 Now $45.73 +20.48% ▼ −4.31% −4.63% vs SPY
Showing 10 of 28

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 24, 2026